Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Vladimir E Medvedev. (2017) Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE. Neuropsychiatric Disease and Treatment 13, pages 1141-1151.
Read now
Read now
Ruiying Kang, Yan He, Yuxiang Yan, Zhiwu Li, Yeqing Wu, Xiaojuan Guo, Zhigang Liang & Jun Jiang. (2015) Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial. Neuropsychiatric Disease and Treatment 11, pages 1307-1311.
Read now
Read now
Articles from other publishers (8)
RenukaL Kadam, SmitaDipak Sontakke, Prashant Tiple, VijayM Motghare, ChaitaliS Bajait & MrunaliniV Kalikar. (2020) Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study. Indian Journal of Pharmacology 52:2, pages 79.
Crossref
Crossref
Benjamin N. Greenwood. (2019) The role of dopamine in overcoming aversion with exercise. Brain Research 1713, pages 102-108.
Crossref
Crossref
Rebecca Robillard, Joanne S. Carpenter, Kristy-Lee Feilds, Daniel F. Hermens, Django White, Sharon L. Naismith, Delwyn Bartlett, Bradley Whitwell, James Southan, Elizabeth M. Scott & Ian B. Hickie. (2018) Parallel Changes in Mood and Melatonin Rhythm Following an Adjunctive Multimodal Chronobiological Intervention With Agomelatine in People With Depression: A Proof of Concept Open Label Study. Frontiers in Psychiatry 9.
Crossref
Crossref
Gregory M. Brown, Roger S. McIntyre, Joshua Rosenblat & Rüdiger Hardeland. (2018) Depressive disorders: Processes leading to neurogeneration and potential novel treatments. Progress in Neuro-Psychopharmacology and Biological Psychiatry 80, pages 189-204.
Crossref
Crossref
Jin-Yi Hyeon, Eun-Young Choi, So-Hui Choe, Hae Ryoun Park, Jeom-Il Choi, In Soon Choi & Sung-Jo Kim. (2017) Agomelatine, a MT1/MT2 melatonergic receptor agonist with serotonin 5-HT2C receptor antagonistic properties, suppresses Prevotella intermedia lipopolysaccharide-induced production of proinflammatory mediators in murine macrophages. Archives of Oral Biology 82, pages 11-18.
Crossref
Crossref
Venkataramanujam Srinivasan, Domenico de Berardis, Michele Fornaro, Francisco López-Muñoz, Timo Partonen & Rahimah Zakaria. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
117
127
.
Venkataramanujam Srinivasan, Domenico de Berardis, Michele Fornaro, Francisco Lopez-Muñoz, Rahimah Zakaria, Mohd Jamil Yaacob & Zahiruddin Othman. 2016. Melatonin, Neuroprotective Agents and Antidepressant Therapy. Melatonin, Neuroprotective Agents and Antidepressant Therapy
219
228
.
F İlkaya, M Yüce, AE Ağrı, H Güzel, H Balcı, F Uçar, Z Babadağı, M Müjdeci & E Mutlu. (2014) The combination of agomelatine and ritanserin exerts a synergistic interaction in passive avoidance task. Human & Experimental Toxicology 34:8, pages 787-795.
Crossref
Crossref